NCT06314334View on ClinicalTrials.gov

Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

March 4, 2023

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Interventions
DRUG

Sintilimab+Pegaspargase

"1. Sintilimab, 200mg intravenous drip, on day 1;~2. pegaspargase, 2000U/m\^2, capped at 3750U, intramuscular, day 1;"

DRUG

P-GemOx

"1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip"

DRUG

GELAD

"1. gemcitabine 1.0g/m\^2 on day 1, intravenous drip;~2. etoposide 60mg/m\^2 on day 1-3, intravenous drip;~3. pegaspargase 2000U/m\^2, capped at 3750U on day 1,intramuscular;~4. dexamethasone 20mg on day 1-4, intravenous drip."

RADIATION

IMRT

Intensity modulated radiotherapy (50-56Gy)

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER